NKTR
Nektar TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-27
Current thesis
Rezpegaldesleukin has now produced supportive AD and AA data, the company says Phase 3 AD starts in Q2 2026, and the February financing materially improved near-term flexibility [#IR-2026-03-28] [#10-K-2026-03-13].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.9.
What can break
2026 operating cash burn rises faster than investors expect despite the February raise and ATM proceeds
Momentum
38
Value
41
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $78.00 · Bull $105.00 · Bear $52.00
Data freshness
Prices
As of 2026-07-27
Fundamentals
As of 2026-07-27 • Vendor: Data Vendor v1
Scores
As of 2026-07-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-27
Investment thesis
As of 2026-07-27
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $153.22
Why
Momentum38 · Δ7d -0.3
Value41 · Δ7d 0.0
Sentiment54 · Δ7d -5.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
38
26% active weight
Current posture
7d trendImproving
Δ7d
-0.3
Δ21d
+19.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
54
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.9
Δ21d
-6.8
Why this grade
Composite grade D. Momentum 37.6 / Value 41.1 / Sentiment 53.7
Fundamentals (TTM)As of 2026-07-27
Fundamentals (TTM)
As of 2026-07-27
Market Cap
$2.41B
Beta
1.35
Shares Out
33.79M
P/E (TTM) · Derived
-7.3
P/S (TTM)
14.45
P/FCF (TTM) · Derived
-6.59
Rev YoY
+3.8%
EPS YoY
-49.8%
Gross Margin
+98.7%
Op Margin
-156.7%
Net Debt
-$96.84M
Current Ratio
10.21
As of 2026-07-27 • Updated nightlySource: Internal modelMethodology